AVEO Pharmaceuticals, Inc. (AVEO)
(Delayed Data from NSDQ)
$0.94 USD
+0.04 (4.01%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.91 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[AVEO]
Reports for Purchase
Showing records 1 - 20 ( 136 total )
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
AVEO to Become LG Chem''s US Beachhead; Downgrade to Neutral With a $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Long-Term and NccRCC Results at ASCO Continue to Favor Fotivda; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Fotivda Continues to Deliver; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Encouraging Fotivda Launch Metrics; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Fotivda Launch Momentum Continues; TiNivo-2 Study Started; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Fotivda Launch off to a Strong Start; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Upcoming Fotivda KOL Webinar; Lower PT to $19 on Early Launch Metrics; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Registration Plans for Ficlatuzumab Announced; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Fotivda Launched; Ficlatuzumab Data at ASCO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Key Takeaways From KOL Call on Advanced RCC and Fotivda; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Advanced RCC - What to Expect From Fotivda?s (tivozanib) Launch?
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Preparing for a Successful Fotivda Launch; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Tivozanib Approved Earlier Than Expected; Higher $27PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Biotech Should Keep the Wind at its Back in 2021; Top Healthcare Picks
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
All Eyes on FDA Decision on Tivozanib; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Return of Ficlatuzumab Rights Opens the Path to a Pivotal Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department